Delta‑like ligand 4: A predictor of poor prognosis in clear cell renal cell carcinoma

Wang,Wei; Yu,Yi; Wang,Ya; Li,Xiaoming; Bao,Junsheng; Wu,Gongjin; Chang,Hong; Shi,Tingkai; Yue,Zhongjin

doi:10.3892/ol.2014.2554

Delta‑like ligand 4: A predictor of poor prognosis in clear cell renal cell carcinoma

Authors:
- Wei Wang
- Yi Yu
- Ya Wang
- Xiaoming Li
- Junsheng Bao
- Gongjin Wu
- Hong Chang
- Tingkai Shi
- Zhongjin Yue
View Affiliations

Affiliations: Department of Urology, Institute of Urology, Gansu Nephro‑Urological Clinical Center, The Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China, Department of Gastroenterology, The Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China, Department of Nephrology, The Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China, Department of Pathology, The Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China
Published online on: September 24, 2014 https://doi.org/10.3892/ol.2014.2554
Pages: 2627-2633

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Delta‑like ligand 4 (Dll4)‑Notch signaling is important in tumor angiogenesis; however, the prognostic value of D114 detection in patients with clear cell renal cell carcinoma (CCRCC) remains unclear. The present study aimed to determine whether the presence of high Dll4 expression levels was correlated with poor prognosis in CCRCC following curative resection. The D114 expression levels in four paired samples of CCRCC tissues and adjacent normal renal tissues were assayed by western blotting. Surgical specimens comprised 121 CCRCC tissue samples and 65 normal renal tissue samples, obtained from patients with CCRCC. The specimens were immunohistochemically assessed to determine Dll4 and vascular endothelial growth factor receptor 2 (VEGFR‑2) expression levels. The prognostic significance of Dll4 expression levels was evaluated by the Kaplan‑Meier method and Cox regression analysis. The correlation between Dll4 expression levels and VEGFR‑2 expression levels, tumor stage, tumor grade and metastasis, was examined by χ2 test and multivariate logistic regression. As determined by the western blotting results, Dll4 protein expression levels were significantly increased in CCRCC tissues compared with those in adjacent non‑cancerous tissues. From the analysis of the surgical specimens, 53 (43.8%) CCRCC patients exhibited immunohistochemically high Dll4 expression levels and 68 (56.2%) patients exhibited low Dll4 expression levels. The survival curves revealed that the patients with high Dll4 expression levels had significantly shorter survival times than the patients with low Dll4 expression levels (P<0.001). Multivariate survival analysis demonstrated that the presence of high Dll4 expression levels was independently associated with reduced overall survival and progression‑free survival times (P=0.021 and 0.034, respectively). A positive correlation was also identified between Dll4 and VEGFR‑2 expression levels (P=0.001). In conclusion, the results show that the presence of high Dll4 expression levels was clearly associated with high VEGFR‑2 expression levels, tumor grade, tumor stage and poor prognosis in CCRCC patients. Therefore, inhibition of Dll4 may exert potent growth inhibitory effects on tumors resistant to anti‑VEGF therapies for CCRCC.

View Figures

View References

1	van Spronsen DJ, Mulders PF and De Mulder PH: Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 55:177–191. 2005.
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010.
3	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005.
4	Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996.
5	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008.
6	Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 3:24–40. 2006.
7	Lai EC: Notch signaling: control of cell communication and cell fate. Development. 131:965–973. 2004.
8	Kopan R and Ilagan MX: The canonical notch signaling pathway: unfolding the activation mechanism. Cell. 137:216–233. 2009.
9	Noguera-Troise I, Daly C, Papadopoulos NJ, et al: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 444:1032–1037. 2006.
10	Hellström M, Phng LK, Hofmann JJ, et al: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 445:776–780. 2007.
11	Lobov IB, Renard RA, Papadopoulos N, et al: Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci USA. 104:3219–3224. 2007.
12	Hoey T, Yen WC, Axelrod F, et al: DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell. 5:168–177. 2009.
13	Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R and Ish-Horowicz D: Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation. 69:135–144. 2001.
14	Patel NS, Dobbie MS, Rochester M, et al: Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res. 12:4836–4844. 2006.
15	Jubb AM, Soilleux EJ, Turley H, et al: Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol. 176:2019–2028. 2010.
16	Jubb AM, Turley H, Moeller HC, et al: Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer. 101:1749–1757. 2009.
17	Patel NS, Li JL, Generali D, Poulsom R, Cranston DW and Harris AL: Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 65:8690–8697. 2005.
18	Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT and Bremnes RM: Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer. 116:5676–5685. 2010.
19	Chen HT, Cai QC, Zheng JM, et al: High Expression of Delta-Like Ligand 4 Predicts Poor Prognosis After Curative Resection for Pancreatic Cancer. Ann Surg Oncol. 19(Suppl 3): S464–S474. 2012.
20	Martínez-Salamanca JI, Huang WC, Millán I, et al: International Renal Cell Carcinoma-Venous Thrombus Consortium: Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol. 59:120–127. 2011.
21	Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–663. 1982.
22	Linehan WM and Zbar B: Focus on kidney cancer. Cancer Cell. 6:223–228. 2004.
23	Suchting S, Freitas C, le Noble F, et al: The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci USA. 104:3225–3230. 2007.
24	Scehnet JS, Jiang W, Kumar SR, et al: Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood. 109:4753–4760. 2007.
25	Zhang JX, Cai MB, Wang XP, et al: Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma. Med Oncol. 30:3902013.
26	Ridgway J, Zhang G, Wu Y, et al: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 444:1083–1087. 2006.
27	Thurston G, Noguera-Troise I and Yancopoulos GD: The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer. 7:327–331. 2007.
28	Escudier B, Eisen T, Stadler WM, et al: TARGET study group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007.
29	Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356:115–124. 2007.
30	Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 349:427–434. 2003.
31	Ferrara N, Hillan KJ, Gerber H-P and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004.
32	Ebos JM, Lee CR and Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res. 15:5020–5025. 2009.
33	Duda DG, Batchelor TT, Willett CG and Jain RK: VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 13:223–230. 2007.
34	Kuhnert F, Kirshner JR and Thurston G: Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell. 3:202011.